肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 1 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.
CD70 是 AML 中 NK 细胞免疫治疗的一个有前景的靶点。然而，AML 细胞上 HLA 分子的 IFN-γ依赖性上调导致对 ADCC 的耐药。这些发现强调了在临床试验中需要合理的联合策略来克服这种可诱导的免疫逃逸机制。
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
PIs 在体外和体内增强表达 CAR 的同种异体 NK 细胞对急性髓系白血病的抗白血病疗效，值得在早期临床试验中进一步探索这种联合治疗。
Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation.
Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.
CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions.
Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.
Recent advances in CAR T and CAR NK cell therapy for AML.
Current and future perspectives of chimeric antigen receptors against glioblastoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
